{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:51:53Z","timestamp":1740135113440,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3465-2","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T09:38:45Z","timestamp":1542361125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The efficacy of paritaprevir\/ritonavir\/ombitasvir+dasabuvir and ledipasvir\/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5406-4603","authenticated-orcid":false,"given":"Ewa","family":"Janczewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Berak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Piekarska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Gietka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Dybowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u0142odzimierz","family":"Mazur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Belica-Wdowik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Witold","family":"Dobracki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Tudrujek-Zdunek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zbigniew","family":"Dero\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Buczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Sitko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Czau\u017c-Andrzejuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Lorenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Bia\u0142kowska-Warzecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jolanta","family":"Citko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Laurans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerzy","family":"Jaroszewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Socha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Tronina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brygida","family":"Adamek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Horban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waldemar","family":"Halota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Baka-\u0106wierz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Tomasiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksander","family":"Garlicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Wawrzynowicz-Syczewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"3465_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/MEG.0000000000001106","volume":"30","author":"N Kobayashi","year":"2018","unstructured":"Kobayashi N, Iijima H, Tada T, Kumada T, Yoshida M, Aoki T, et al. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Eur J Gastroenterol Hepatol. 2018;30:546\u201351. \nhttps:\/\/doi.org\/10.1097\/MEG.0000000000001106\n\n.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3465_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1111\/apt.14554","volume":"47","author":"T Tada","year":"2018","unstructured":"Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, et al. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2018;47:1012\u201322. \nhttps:\/\/doi.org\/10.1111\/apt.14554\n\n.","journal-title":"Aliment Pharmacol Ther"},{"key":"3465_CR3","first-page":"587","volume":"13","author":"HD Trivedi","year":"2017","unstructured":"Trivedi HD, Lin SC, TY Lau D. Noninvasive Assessment of Fibrosis Regression in Hepatitis C Virus Sustained Virologic Responders. Gastroenterol Hepatol. 2017;13:587\u201395.","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"3465_CR4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/liv.13629","volume":"38","author":"Karin Kozbial","year":"2017","unstructured":"Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, et al. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon\/ribavirin-free treatment. Liver Int. 2017. \nhttps:\/\/doi.org\/10.1111\/liv.13629\n\n.","journal-title":"Liver International"},{"issue":"1","key":"3465_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/hep4.1050","volume":"22","author":"SR Bartlett","year":"2017","unstructured":"Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, Miller V, et al. Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: a systematic review. Hepatol Commun. 2017;22(1):379\u201390. \nhttps:\/\/doi.org\/10.1002\/hep4.1050\n\n.","journal-title":"Hepatol Commun"},{"key":"3465_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/03009734.2018.1441928","volume":"123","author":"M Kjellin","year":"2018","unstructured":"Kjellin M, Wessl\u00e9n T, L\u00f6fblad E, Lennerstrand J, Lannerg\u00e5rd A. The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort. Ups J Med Sci. 2018;123:50\u20136. \nhttps:\/\/doi.org\/10.1080\/03009734.2018.1441928\n\n.","journal-title":"Ups J Med Sci"},{"key":"3465_CR7","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1038\/s41598-018-21303-2","volume":"8","author":"GP Wang","year":"2018","unstructured":"Wang GP, Terrault N, Reeves JD, Liu L, Li E, Zhao L, et al. Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir\/sofosbuvir or simeprevir\/sofosbuvir against GT1 HCV infection. Sci Rep. 2018;8:3199. \nhttps:\/\/doi.org\/10.1038\/s41598-018-21303-2\n\n.","journal-title":"Sci Rep"},{"key":"3465_CR8","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. 2015. J Hepatol. 2015;63:199\u2013236.","DOI":"10.1016\/j.jhep.2015.03.025"},{"issue":"3","key":"3465_CR9","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"Hepatitis C Guidance","year":"2015","unstructured":"Hepatitis C Guidance. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. HEPATOLOGY. 2015;62(3):932\u201354.","journal-title":"HEPATOLOGY"},{"issue":"16","key":"3465_CR10","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483\u201393. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1316366\n\n.","journal-title":"N Engl J Med"},{"key":"3465_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","volume":"15","author":"M Bourli\u00e8re","year":"2015","unstructured":"Bourli\u00e8re M, Bronowicki JP, de Ledinghen V, H\u00e9zode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15:397\u2013404. \nhttps:\/\/doi.org\/10.1016\/S1473-3099(15)70050-2\n\n.","journal-title":"Lancet Infect Dis"},{"issue":"9916","key":"3465_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515\u201323. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(13)62121-2\n\n.","journal-title":"Lancet"},{"key":"3465_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211\u201321. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1306218\n\n.","journal-title":"N Engl J Med"},{"issue":"9","key":"3465_CR14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/apt.13790","volume":"44","author":"R Flisiak","year":"2016","unstructured":"Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zar\u0119bska-Michaluk D, Nazzal K, et al. Real-world effectiveness and safety of ombitasvir\/paritaprevir\/ritonavir \u00b1 dasabuvir \u00b1 ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016;44(9):946\u201356. \nhttps:\/\/doi.org\/10.1111\/apt.13790\n\n.","journal-title":"Aliment Pharmacol Ther"},{"key":"3465_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5114\/ceh.2016.59099","volume":"2","author":"W Halota","year":"2016","unstructured":"Halota W, Flisiak R, Boro\u0144-Kaczmarska A, Juszczyk J, Ma\u0142kowski P, Paw\u0142owska M, et al. Recommendations for the treatment of hepatitis C issued by the polish group of HCV experts \u2013 2016. Clin Exp Hepatol. 2016;2:27\u201333. \nhttps:\/\/doi.org\/10.5114\/ceh.2016.59099\n\n.","journal-title":"Clin Exp Hepatol."},{"key":"3465_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5114\/ceh.2016.63871","volume":"2","author":"R Flisiak","year":"2016","unstructured":"Flisiak R, Pogorzelska J, Berak H, Horban A, Or\u0142owska I, Simon K, et al. Prevalence of HCV genotypes in Poland - the EpiTer study. Clin Exp Hepatol. 2016;2:144\u20138. \nhttps:\/\/doi.org\/10.5114\/ceh.2016.63871\n\n.","journal-title":"Clin Exp Hepatol."},{"issue":"2","key":"3465_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5114\/ceh.2017.67782","volume":"3","author":"W Halota","year":"2017","unstructured":"Halota W, Flisiak R, Juszczyk J, Ma\u0142kowski P, Paw\u0142owska M, Simon K, et al. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol. 2017;3(2):47\u201355 \nhttps:\/\/doi.org\/10.5114\/ceh.2017.67782\n\n.","journal-title":"Clin Exp Hepatol"},{"key":"3465_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1471-2334-10-212","volume":"10","author":"FL Gon\u00e7ales Jr","year":"2010","unstructured":"Gon\u00e7ales FL Jr, Moma CA, Vigani AG, Ngerami AF, Gon\u00e7ales ES, Tozzo R, et al. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life. BMC Infect Dis. 2010;10:212. \nhttps:\/\/doi.org\/10.1186\/1471-2334-10-212\n\n.","journal-title":"BMC Infect Dis"},{"key":"3465_CR19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00535-011-0409-7","volume":"46","author":"T Oze","year":"2011","unstructured":"Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, et al. Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. J Gastroenterol. 2011;46:1031\u20137. \nhttps:\/\/doi.org\/10.1007\/s00535-011-0409-7\n\n.","journal-title":"J Gastroenterol"},{"issue":"4","key":"3465_CR20","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","volume":"130","author":"T Berg","year":"2006","unstructured":"Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon- alfa-2a plus ribavirin. Gastroenterology. 2006;130(4):1086\u201397.","journal-title":"Gastroenterology"},{"key":"3465_CR21","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"I Jacobson","year":"2011","unstructured":"Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405\u201316.","journal-title":"N Engl J Med"},{"issue":"13","key":"3465_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195\u2013206.","journal-title":"N Engl J Med"},{"issue":"25","key":"3465_CR23","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417\u201328.","journal-title":"N Engl J Med"},{"issue":"13","key":"3465_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207\u201317.","journal-title":"N Engl J Med"},{"key":"3465_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","volume":"15","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis. 2015;15:27\u201335. \nhttps:\/\/doi.org\/10.1016\/S1473-3099(14)71002-3\n\n Erratum in: \nLancet Infect Dis. 2016 Apr;16(4):404\n\n.","journal-title":"Lancet Infect Dis"},{"key":"3465_CR26","doi-asserted-by":"publisher","first-page":"777.e1","DOI":"10.1016\/j.cmi.2017.04.005","volume":"23","author":"V Cento","year":"2017","unstructured":"Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, et al. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. Clin Microbiol Infect. 2017;23:777.e1\u20134. \nhttps:\/\/doi.org\/10.1016\/j.cmi.2017.04.005\n\n.","journal-title":"Clin Microbiol Infect"},{"key":"3465_CR27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/jvh.12708","volume":"24","author":"TM Welzel","year":"2017","unstructured":"Welzel TM, Hinrichsen H, Sarrazin C, Buggisch P, Baumgarten A, Christensen S, et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir\/paritaprevir\/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German hepatitis C registry. J Viral Hepat. 2017;24:840\u20139.","journal-title":"J Viral Hepat"},{"key":"3465_CR28","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","volume":"66","author":"JL Calleja","year":"2017","unstructured":"Calleja JL, Crespo J, Rinc\u00f3n D, Ruiz-Antor\u00e1n B, Fernandez I, Perell\u00f3 C, et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCVgenotype 1 infection: results from a Spanish real-world cohort. J Hepatol. 2017;66:1138\u201348. \nhttps:\/\/doi.org\/10.1016\/j.jhep.2017.01.028\n\n.","journal-title":"J Hepatol"},{"issue":"4","key":"3465_CR29","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","volume":"154","author":"J Dietz","year":"2018","unstructured":"Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, et al. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. Gastroenterology. 2018;154(4):976\u2013988.e4. \nhttps:\/\/doi.org\/10.1053\/j.gastro.2017.11.007\n\n.","journal-title":"Gastroenterology"},{"key":"3465_CR30","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/liv.13327","volume":"37","author":"VC Di Maio","year":"2017","unstructured":"Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, et al. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514\u201328. \nhttps:\/\/doi.org\/10.1111\/liv.13327\n\n.","journal-title":"Liver Int"},{"issue":"5","key":"3465_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jvh.12850","volume":"25","author":"R. Kozuka","year":"2018","unstructured":"Kozuka R, Hai H, Motoyama H, Fujii H, Uchida-Kobayashi S, Morikawa H, et al. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-na\u00efve patients with chronic HCV genotype 1b infection in a real-world cohort. J Viral Hepat. 2017. \nhttps:\/\/doi.org\/10.1111\/jvh.12850\n\n.","journal-title":"Journal of Viral Hepatitis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3465-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3465-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T13:05:58Z","timestamp":1578575158000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3465-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3465"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3465-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"22 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective, observational study was carried out in real-life setting, with approved drugs. Patients were not exposed to any experimental interventions nor did the study intervene with the clinical management of the patient. The study only collected information from patient records. The analysis included routine examinations and tests performed in patients treated within the therapeutic program of the National Health Fund. The data was originally collected to assess treatment efficacy and safety in individual patient, not for scientific purposes. Hence, the treating physicians did not take approval from the ethics committee of any research\/academic institute. According to local law (Pharmaceutical Law of 6th September 2001, art. 37al) non-interventional studies do not require approval of ethics committee. Patients signed informed consent for treatment and processing of personal data. Patients\u2019 data were collected through an on-line system and only physicians who have patients in care had access to patients\u2019 personal information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript doesn\u2019t contain details, images, or videos relating to an individual person.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EJ has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from Abbvie, Allergan, Bristol Meyer Squibb, Gilead Sciences, Janssen Cilag, MSD, Vertex, Tobira. AP has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from: AbbVie, Gilead, Merck, Roche. WM has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from: AbbVie, BMS, Gilead, Janssen, Merck, Roche. TBM has received research grants and fees for scientific consultancies for: AbbVie, Gilead. WD has received fees for scientific consultancies from: AbbVie, Gilead. ACA has received research grants from: AbbVie, Merck. JJ has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from: AbbVie, BMS, Gilead, Merz, Roche. \u0141S has received fees for scientific consultancies from BMS. BA has received research grants from BMS and fees for scientific consultancies from Roche, AbbVie, BMS, Gilead, MSD. WH has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from: AbbVie, BMS, Gilead, Janssen, Merck, Roche. BBC has received research grants and\/or fees for lectures, scientific consultancies from: AbbVie, Gilead, Roche. KT has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from: AbbVie, Alfa Wasserman, BMS, Gilead, Janssen, Merck, Roche. KS has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from: AbbVie, Gilead, BMS, Merck, Janssen, Alfa-Wassermann, Baxter, Bayer, Roche Allergan, EISAI, Gilead, Intercept, Tobira, Pfizer.AG has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from: AbbVie, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Roche, Sanofi Pasteur, Amgen, Pfizer. MWS has received fees for lectures, scientific consultancies from: Gilead, AbbVie, Merck. RF has received research grants and\/or fees for lectures, advisory boards, scientific consultancies from: AbbVie, Alfa Wasserman, BMS, Gilead, Janssen, Merck, Roche, Shionogi. DZM, HB, DD, MTZ, ZD, IB, MS, BL, JBW, JC, \u0141L, OT, AH, AG declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"580"}}